CENTREVILLE, Va., Jan. 25 /PRNewswire/ -- Octapharma is pleased to announce its decision to become a member of the Biotechnology Industry Organization. Membership in BIO brings substantial benefits to Octapharma. Among these is the Association's considerable influence on the U.S. legislative process and on regulatory bodies. Representing some of the largest and most research intensive pharmaceutical companies, BIO's voice is heard where smaller groups are not. With reimbursement of biologicals becoming a significant problem in patient access to product, this influence will be critical in providing essential input into federal and state reimbursement policies and resolving access issues.
Additionally, BIO has made a concerted effort to develop a constituency of plasma derivative manufacturers. For those plasma derivative manufacturers who are currently members, BIO has become a leading source of advanced information on government and private policies relevant to the plasma derivative industry. BIO also coordinates its policy position with patient groups though its Outreach/Alliance Development Committee and other mechanisms that host regular briefings, tours and recognition events for health advocacy groups.
Finally, Octapharma believes that its decision to join BIO is consistent with its future plans and with its new mission statement, "for the safe and optimal use of human proteins." With much of the BIO membership focusing on leading edge research in genetic modifications of peptides and proteins, bioprocessing, and bioinformatics, there would appear to be great opportunities for commercial collaboration and cross-fertilization.
Octapharma welcomes the opportunity to be a part of this leading Association!
Octapharma is a leading provider of human plasma based
biopharmaceuticals to healthcare professionals and consumers worldwide.
Since its founding in 1983, the name Octapharma has become synonymous with
ethical and responsible pr
Copyright©2008 PR Newswire.
All rights reserved